Perman Jorayev, Ph.D.

Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.

Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.

Zero Point Motion creates chipscale optical inertial sensors that are 100x more accurate than those available today to improve positioning and navigation for high volume markets. The company is headquartered in Bristol, UK and funded by deep tech venture capital firms. Were hiring! Apply here https://tinyurl.com/4bjajm93 Find out more, visit: www.zeropointmotion.com

Biograil™ is a pre-clinical stage pharmaceutical company leveraging its proprietary BIONDD™ technology to unlock the potential of transforming the tremendous market of injectable pharmaceutical products into convenient oral capsules. We strive to make the most effective and convenient pharmaceuticals to patients in innovative and prioprietary ways by combining known technologies.

Nagi Bioscience is a pioneering high-tech startup developing NextGen laboratory equipment to unlock the full potential of alternatives to animal testing. Located in the heart of the Swiss "Health Valley”, we work for the transformation of biological testing standards providing cutting-edge equipment to achieve faster, scalable, more efficient and ethical methods. Under the motto “in vivo testing at the in vitro scale”, our technologies are accelerating drug development pipelines and introducing new toxicology testing standards revolutionizing pharmaceutical, cosmetic, and agro-chemical industries among others. Our approach? To unlock the full potential of small organisms, such as the well-characterized C. elegans nematode, for high-content screening of substances for safety and efficacy testing.

At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

Amadeus Capital Partners is a global technology investor. Since 1997, the firm has raised over $1bn for investment and used it to back more than 180 companies. With vast experience and a great network, Amadeus’ team of investors and entrepreneurs share a passion for the transformative power of technology. Pioneering businesses we’ve backed include cyber security vendor ForeScout (NASDAQ:FSCT); Graphcore, innovators in intelligent microprocessors; IVF genetic testing company, Igenomix; the first single-chip Bluetooth solution, CSR (acquired by Qualcomm); IndiaMART, the B2B online marketplace (NSE: INDIAMART) and speech recognition company VocalIQ (acquired by Apple).

Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.

Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.

Zero Point Motion creates chipscale optical inertial sensors that are 100x more accurate than those available today to improve positioning and navigation for high volume markets. The company is headquartered in Bristol, UK and funded by deep tech venture capital firms. Were hiring! Apply here https://tinyurl.com/4bjajm93 Find out more, visit: www.zeropointmotion.com

Biograil™ is a pre-clinical stage pharmaceutical company leveraging its proprietary BIONDD™ technology to unlock the potential of transforming the tremendous market of injectable pharmaceutical products into convenient oral capsules. We strive to make the most effective and convenient pharmaceuticals to patients in innovative and prioprietary ways by combining known technologies.